All In Biotech

Drug Trial Radar · NCT02279095

An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)

A Phase 2, Open-Label Extension, Efficacy and Safety Study of a Retinoic Acid Receptor Gamma (RARγ) Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)

Last checked: Nov 20, 2026Latest source record: Feb 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

58

Actual

Start

Oct 9, 2014

Primary completion

Sep 20, 2022

Study completion Sep 20, 2022

Sponsor

Lead sponsor
Clementia Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Oct 30, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by heterotopic ossification (HO), i.e., abnormal bone formation, often associated with painful, recurrent episodes of soft tissue swelling (flare-ups). Lesions begin in early childhood and lead to progressive ankyloses of major joints with resultant loss of movement. In this study, the ability of different palovarotene dosing regimens to prevent the formation of new HO will be evaluated in adult and pediatric participants with FOP.

Conditions

  • Fibrodysplasia Ossificans Progressiva

Interventions

  • Palovarotene dose level 1Drug

    Palovarotene was taken orally once daily at approximately the same time each day.

  • Palovarotene dose level 2Drug

    Palovarotene will be taken orally once daily at approximately the same time each day.

  • Palovarotene dose level 3Drug

    Palovarotene will be taken orally once daily at approximately the same time each day.

  • Palovarotene dose level 4Drug

    Palovarotene will be taken orally once daily at approximately the same time each day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts A and B: Percentage of Flare-ups With No New Heterotopic Ossification (HO) at Week 12Time frame: Baseline and Week 12
  2. Parts B and C: Annualized Change in New HO VolumeTime frame: From Baseline (Day 1) up to end of 2 year follow-up period, approximately a maximum of 96 months

Locations

8 sites in 5 countries. Site status is shown where the registry gives one.

  • University of California San Francisco, Division of Endocrinology and Metabolism

    San Francisco, California

  • Mayo Clinic, Department of Medicine

    Rochester, Minnesota

  • University of Pennsylvania, Center for FOP & Related Bone Disorders

    Philadelphia, Pennsylvania

  • Hospital Italiano de Buenos Aires, Department of Pediatrics

    Buenos Aires, Argentina

  • Royal North Shore Hospital

    Saint Leonards, New South Wales, Australia

  • Queensland University of Technology (QUT) Institute of Health and Biomedical Innovation (IHBI)

    Woolloongabba, Queensland, Australia

  • Hôpital Necker-Enfants Malades, Department of Genetics

    Paris, France

  • The Royal National Orthopaedic Hospital, Brockley Hill

    Stanmore, Middlesex, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.